Detail akcie Supernus online

Business Summary: Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is also developing a range of novel CNS product candidates, including new potential treatments for epilepsy, depression, and other CNS disorders. Its commercial products include Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients six years and older.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Supernus Pharmaceuticals Inc revenues increased 4% to $149.8M. Net loss totaled $11.8M vs. income of $124K. Revenues reflect Net product sales-Qelbree segment increase of 44% to $64.7M, Net product sales - GOCOVRI segment increase of 16% to $30.7M. Net loss reflects Contingent consideration loss (gain) increase from $1.1M (income) to $7.7M (expense).